Picture loading failed.

Pre-Made Vofatamab biosimilar, Whole mAb, Anti-FGFR3 Antibody: Anti-ACH/CEK2/JTK4/CD333/HSFGFR3EX therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Vofatamab (B-701, Rainier Therapeutics) is an antibody that targets fibroblast growth factor receptor 3 (FGFR3), an established driver of bladder cancer and other malignancies.

Order information


* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

Catalog No. Package Price(In USD) Qty (Quantity) Sum(In USD)
GMP-Bios-ab-626-1mg 1mg 3090
GMP-Bios-ab-626-10mg 10mg Inquiry
GMP-Bios-ab-626-100mg 100mg Inquiry
GMP-Bios-ab-626-xmg >100mg Inquiry
Shipping Cost: 760.00
Total:



Description

Products Name (INN Index) Pre-Made Vofatamab biosimilar, Whole mAb, Anti-FGFR3 Antibody: Anti-ACH/CEK2/JTK4/CD333/HSFGFR3EX therapeutic antibody
INN Name Vofatamab
TargetFGFR3
FormatWhole mAb
Derivation
Species ReactivityHuman
CH1 IsotypeIgG1
VD LCKappa
Highest_Clin_Trial (Jan '20)Phase-I/II
Est. StatusActive
100% SI StructureNone
99% SI StructureNone
95-98% SI Structure4wv1:BA:ED/3grw:HL
Year Proposed2018
Year Recommended2019
CompaniesBioClin Therapeutics;Rainier Therapeutics
Conditions Approvedna
Conditions ActiveUrogenital cancer
Conditions DiscontinuedMultiple myeloma;Solid tumours;Achondroplasia
Development Techna